1 H NMR (400 MHz, D 2 O) 7.78 (s, 2H), 7.01 (s, 2H), 4.71 4.60 (m, 2H), 4.44 4.03 (m, 3H), 3.80 3.74 (m, 4H), 3.32 2.88 (m, 10H), 1.85 1.11 (m, 18H) 13 .C NMR (151 MHz, D 2 O) 178.88, 172.79, 172.16, 172.10, 167.38, 167.21, 134.76, 134.56, 129.96, 129.66, 117.45, 54.20, 54.17, 53.68, 53.46, 53.08, 40.64, 40.59, 39.33, 39.28, 37.38, 30.79, 30.39, 30.37, 28.05, 27.65, 27.48, 27.40, 22.63, 22.18, 22.04
Protocol: Tesamorelin can be stacked with MOTS-c for a dual-mechanism fat loss approach: tesamorelin mobilizes visceral fat through GH-mediated lipolysis, while MOTS-c increases mitochondrial fat oxidation
Sep 2020;61(9):529-540
Emideltide, also called DSIP, was the only peptide rejected
Involvement of ERK1/2 pathway in BPC-157-induced cell proliferation, migration, and tube formation To explore whether the ERK1/2, JNK, or p38 pathway was involved in BPC-157-induced cell proliferation, migration, and tube formation, PD98059 (ERK1/2 inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38 inhibitor) were used